10.63  4.1 (62.79%)		01-30 16:00
Open: 9.12 High: 11.05 Volume: 7,668,000		Pre. Close: 6.53 Low: 6.58 Market Cap: 332(M)

Short term
Mid term
Targets	6-month :	12.9	1-year :	15.07
Resists	First :	11.05	Second :	12.9
Pivot price	3.04
Supports	First :	4.94	Second :	1.16
MAs	MA(5) :	5.48	MA(20) :	2.64
	MA(100) :	1.78	MA(250) :	1.81
MACD	MACD :	1.2	Signal :	0.5
%K %D	K(14,3) :	91.8	D(3) :	90
RSI	RSI(14): 96.5
52-week	High :	11.05	Low :	0.87

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ANL ] has closed above the upper band by 29.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 1470.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	11.06 - 11.1	11.1 - 11.14
Low:	6.51 - 6.54	6.54 - 6.57
Close:	10.55 - 10.63	10.63 - 10.69

Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Fri, 30 Jan 2026
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Thu, 29 Jan 2026
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update - MarketBeat

Wed, 28 Jan 2026
Individual Investors Are Adlai Nortye Ltd.'s (NASDAQ:ANL) Biggest Owners and Were Rewarded After Market Cap Rose by US$65m Last Week - 富途牛牛

Wed, 28 Jan 2026
Individual investors are Adlai Nortye Ltd.'s (NASDAQ:ANL) biggest owners and were rewarded after market cap rose by US$65m last week - Yahoo Finance

Wed, 28 Jan 2026
Adlai Nortye Ltd.'s (NASDAQ:ANL) market cap surged US$65m last week, retail investors who have a lot riding on the company were rewarded - simplywall.st

Mon, 12 Jan 2026
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Up 6,821.4% in December - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	31 (M)
Shares Float	67 (M)
Held by Insiders	8.5 (%)
Held by Institutions	0 (%)
Shares Short	321 (K)
Shares Short P.Month	9 (K)

EPS	-1.14
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.21
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-29.9 %
Return on Equity (ttm)	-139 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.35
Qtrly Earnings Growth	0 %
Operating Cash Flow	-39 (M)
Levered Free Cash Flow	-38 (M)

PE Ratio	-9.33
PEG Ratio	0
Price to Book value	48.31
Price to Sales	0
Price to Cash Flow	-8.61

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.